In this video, TRxA Executive Director Maaike Everts and Associate Director Michelle Morgan give viewers a short overview of the C-Path’s Translational Therapeutics Accelerator (TRxA) program. TRxA is a global drug discovery and development program focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients. It leverages C-Path’s proficiency in translational and regulatory science to bridge the drug development “valley of death” by providing academic researchers with funding and guidance for the advancement of novel therapeutics from the lab to clinical trials and, ultimately, commercialization and patient care.
